Stay updated with breaking news from Breakthrough Designation. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
BMS-986278 (Bristol Myers Squibb) is a potential first-in-class treatment for progressive pulmonary fibrosis and idiopathic pulmonary fibrosis.
LONDON and SALT LAKE CITY, Sept. 28, 2023 -- Renalytix plc , an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive...
EQS Newswire / 18/09/2023 / 11:40 CET/CEST SINGAPORE - Media OutReach - 18 September 2023 - M&L Healthcare, in its first major MedTech investment, has announced that the U.S. Food and Drug Administration (FDA) has granted premarket approval (PMA) of the LimFlow System - a revolutionary thera...
Revolutionary limb saving procedure set to benefit patients with Chronic Limb-Threatening Ischemia, typically caused by Type 2 DiabetesSINGAPORE - Media OutReach - 15 September...
SUNNYVALE, Calif., Sept. 05, 2023 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary disease, today announced it has finalized external review of interim data and evaluated interim efficacy results for the ongoing Phase III pivotal trial of CardiAMP® Cell Therapy for Heart Failure (CardiAMP HF, clinicaltrials.gov Identifier: NCT02438306), for which the FDA granted Breakthrough Designation fo